Last updated on March 2020

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies


Brief description of study

The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.

Detailed Study Description

The purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683.

The purpose of the phase II of this trial will be to evaluate the anti-tumor activity of MAK683.

Clinical Study Identifier: NCT02900651

Find a site near you

Start Over

Novartis Investigative Site

Hong Kong, Hong Kong
5.77miles
  Connect »